Showing 2931-2940 of 3039 results for "".
- Bausch + Lomb Announces Health Canada Approval Of Vyzulta for the Treatment of Glaucomahttps://modernod.com/news/bausch-lomb-announces-health-canada-approval-of-vyzulta-for-the-treatment-of-glaucoma/2476223/Bausch + Lomb announced that Health Canada issued a Notice of Compliance approving Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Vyzulta is the first prostaglandin analog with one of its metabolites
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Alcon Acquires Tear Film Innovationshttps://modernod.com/news/alcon-announces-acquisition-of-tear-film-innovations/2476248/Alcon announced that it has acquired Tear Film Innovations, maker of the iLux device to treat meibomian gland dysfunction. Financial terms of the deal were not disclosed. Handheld and portable, the iLux enables eye care professionals to directly target a patient’s blocked meibomian
- Mount Sinai Recruits Internationally Recognized Ophthalmologists to Expand Leadershiphttps://modernod.com/news/mount-sinai-recruits-internationally-recognized-ophthalmologists-to-expand-leadership/2479609/Mount Sinai Health System announced the appointment of two new faculty members to expand leadership in the Department of Ophthalmology. Louis R. Pasquale, MD, FARVO, has been named Site Chair of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens and will also serve as Vice Chair of
- RetinaLyze Receives Funding to Detect Diseases Such as Alzheimer’s Using AIhttps://modernod.com/news/retinalyze-receives-funding-to-detect-diseases-such-as-alzheimers-using-ai/2479612/RetinaLyze System A/S (Ltd.), a Denmark-based medical technology company that specializes in retinal imaging screening software, has received funding from The European Regional Development Fund (ERDF) and Central Denmark Region. The funding will be used to explore and develop novel AI-based solut
- Bausch Health to Purchase Majority of Synergy Pharmaceuticals’ Assets, Including Trulancehttps://modernod.com/news/bausch-health-to-purchase-majority-of-synergy-pharmaceuticals-assets-including-trulance/2479614/Bausch Health announced a deal to purchase nearly all of the assets of bankrupt drugmaker Synergy Pharmaceuticals for about $200 million in cash, with the transaction including the constipation treatment Trulance (plecanatide), according to FirstWord. Bausch Health CEO Joseph Papa noted that the
- GenSight Biologics Reports Sustained Quality of Life Improvements at Week 72 of Phase 3 REVERSE Clinical Trialhttps://modernod.com/news/gensight-biologics-reports-sustained-quality-of-life-improvements-at-week-72-of-phase-3-reverse-clinical-trial/2479619/GenSight Biologics reported that week 72 analyses of the data from its phase 3 REVERSE clinical trial revealed a sustained improvement in composite scores and selected sub-scores of a questionnaire used to measure patient perceptions of vision-related quality of life and ability to carry out dail
- Clearside Presents Additional Analyses of PEACHTREE Clinical Trial Data in Support of Xipere in Treating Uveitic Macular Edemahttps://modernod.com/news/clearside-presents-additional-analyses-of-peachtree-clinical-trial-data-in-support-of-xipere-in-treating-uveitic-macular-edema/2476155/Clearside Biomedical recently announced that additional data from PEACHTREE, the company’s pivotal phase 3 trial of Xipere (formerly suprachoroidal CLS-TA) in patients with uveitic macular edema, were presented by Rahul N. Khurana, MD, Vitreoretinal Surgeon at Northern California
- Study: Ocular Technology Provides Early Detection of Alzheimer’s Diseasehttps://modernod.com/news/study-ocular-technology-provides-early-detection-of-alzheimers-disease/2479626/A recent study from JAMA Ophthalmology finds that a specific type of noninvasive eye testing procedure may help assess risk for Alzheimer’s disease. One in 10 Americans over the age 65 has Alzheimer’s, while one-third over the age of 85 have the disease. Fortunately, res
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom